Citadel Advisors
TXG icon

Citadel Advisors’s 10x Genomics TXG Stock Holding History

Citadel Advisors’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.41M Buy
36,900
+23,600
+177% +$618K ﹤0.01% 7357
2026
Q1 		$282K Buy
13,300
+2,800
+27% +$56K ﹤0.01% 10600
2025
Q4 		$171K Sell
10,500
-33,500
-76% -$506K ﹤0.01% 11177
2025
Q3 		$514K Buy
44,000
+700
+2% +$9.13K ﹤0.01% 9067
2025
Q2 		$501K Sell
43,300
-6,600
-13% -$60.2K ﹤0.01% 8621
2025
Q1 		$436K Buy
49,900
+5,500
+12% +$69.3K ﹤0.01% 8778
2024
Q4 		$638K Buy
44,400
+16,200
+57% +$256K ﹤0.01% 8008
2024
Q3 		$637K Buy
28,200
+9,700
+52% +$201K ﹤0.01% 7749
2024
Q2 		$360K Buy
18,500
+8,600
+87% +$225K ﹤0.01% 8754
2024
Q1 		$372K Sell
9,900
-23,800
-71% -$1.05M ﹤0.01% 9005
2023
Q4 		$1.89M Sell
33,700
-12,100
-26% -$527K ﹤0.01% 5463
2023
Q3 		$1.89M Buy
45,800
+16,200
+55% +$843K ﹤0.01% 5321
2023
Q2 		$1.65M Sell
29,600
-41,700
-58% -$2.26M ﹤0.01% 5497
2023
Q1 		$3.98M Buy
71,300
+50,400
+241% +$2.35M ﹤0.01% 4171
2022
Q4 		$762K Sell
20,900
-3,700
-15% -$121K ﹤0.01% 7364
2022
Q3 		$701K Sell
24,600
-38,100
-61% -$1.45M ﹤0.01% 7741
2022
Q2 		$2.84M Buy
62,700
+36,900
+143% +$1.91M ﹤0.01% 4857
2022
Q1 		$1.96M Buy
25,800
+13,200
+105% +$1.15M ﹤0.01% 6122
2021
Q4 		$1.88M Sell
12,600
-91,200
-88% -$14M ﹤0.01% 6404
2021
Q3 		$15.1M Buy
103,800
+93,700
+928% +$16.1M ﹤0.01% 2420
2021
Q2 		$1.98M Sell
10,100
-2,000
-17% -$362K ﹤0.01% 6644
2021
Q1 		$2.19M Sell
12,100
-3,400
-22% -$587K ﹤0.01% 6179
2020
Q4 		$2.19M Sell
15,500
-5,400
-26% -$784K ﹤0.01% 5170
2020
Q3 		$2.61M Buy
20,900
+7,100
+51% +$745K ﹤0.01% 4232
2020
Q2 		$1.23M Buy
13,800
+1,700
+14% +$132K ﹤0.01% 5438
2020
Q1 		$754K Buy
12,100
+800
+7% +$62.4K ﹤0.01% 5807
2019
Q4 		$862K Buy
+11,300
New +$679K ﹤0.01% 5867

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citadel Advisors's TXG Position: Q2 2026 in Review

Citadel Advisors increased its 10x Genomics (TXG) stake by 274% in Q2 2026, buying an estimated $53.3M and bringing the position to 2,779,213 shares worth $107M. The position accounts for 0.01% of the portfolio, ranked #928.

Citadel Advisors first reported a position in TXG in Q3 2019 and has held it in 26 quarters since. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Citadel Advisors held 2,779,213 shares of 10x Genomics worth $107M as of Q2 2026.
  • Citadel Advisors bought 2,035,479 10x Genomics shares in Q2 2026, an estimated $53.3M.
  • 10x Genomics made up 0.01% of Citadel Advisors's portfolio in Q2 2026, its #928 holding.
  • Citadel Advisors first reported a position in 10x Genomics in Q3 2019 and has held it in 26 quarters since.
  • 392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.